Passage Reagent Group™ (4Z0-800) - Cell Systems
Passage Reagent Group™ is a matched set of Cell Systems Certified™ reagents for releasing cells from culture for subculture or freezing.
This PRG Group™ is qualified for use with all Cell Systems Certified Mediums. The PRG contains three parts: PRG-1™ (EDTA-dPBS Solution), PRG-2™ (Trypsin/EDTA-dPBS Solution) and PRG-3™(Trypsin Inhibitor-dPBS Solution) each in a 100mL bottle. Cell Systems media and reagents are Sterile, made with WFI and all components are cGMP and ISO Compliant.
Cell membranes are materially and cumulatively damaged whenever cells are exposed to serine proteases, physically manipulated, centrifuged, and/or frozen. Use of the PRG greatly minimizes damage and stress to cells during passage or freezing of cell cultures.
PRG-1™ (EDTA-dPBS Solution): The chelating agent EDTA in PRG-1™ prepares the cells for PRG-2™ processing.
PRG-2™: Contains highly purified trypsin, allowing a substantial reduction (40%) in the amount of enzyme required to detach cells compared to typical commercial trypsin solutions. The trypsin in PRG-2™ is inactivated by trypsin inhibitors in the PRG-3™ formulation, preventing nonspecific protease damage to cell membranes after detachment.
PRG-3™: Inactivates the protease in PRG-2™ and stabilizes the cell membranes for passaging and freezing. PRG-3™ is engineered to work together with Attachment Factor™ (Cat. #4Z0-210) to stabilize the cell membrane and promote spreading and the establishment of correct polarity after subculture.
Our Passage Reagent System™ (cat. #4Z0-840), adds AttachmentFactor™ to the PRG Group™.
Storage and Handling
Store at -20°C. Once opened, shelf life 30 days at +4 - 8°C
Cell Systems media and reagents are made with WFI, all components are cGMP and ISO Compliant, and are classed "Sterile".
InstructionsClick to view the Passage Reagent Group Protocol
- "Optimization of an in vitro human blood–brain barrier model: Application to blood monocyte transmigration assays" Paradis et al. MethodsX, 2016
- "Shiga Toxin Mediated Neurologic Changes in Murine Model of Disease" Pradhan et al. Frontiers in Cellular and Infection Microbiology, 2016
- "Adenosine Kinase Inhibition Protects The Kidney Against Streptozotocin-Induced Diabetes Through Anti-inflammatory and Anti-oxidant" Mechanisms" Pye et al. Pharmacological Research, 2015
- "S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis" Abu El-Asrar et al. Molecular Vision, 2014)
- "Differential expression and role of hyperglycemia induced oxidative stress in epigenetic regulation of β1, β2 and β3-adrenergic receptors in retinal endothelial cells" Safi et al. BMC Medical Genomics, 2014
- "Optical Recording Reveals Novel Properties of GSK1016790A-Induced Vanilloid Transient Receptor Potential Channel TRPV4 Activity in Primary Human Endothelial Cells" Sullivan et al. Molecular Pharmacology, 2012
- "High-Glucose-Induced Endothelial Cell Injury Is Inhibited by a Peptide Derived from Human Apolipoprotein E." Bhattacharjee et al. PLoS One, 2012
- "Soluble aggregates of the amyloid-beta are trapped by serum albumin to enhance amyloid-beta activation of endothelial cells" Moss et al. Journal of Biological Engineering, 2009